A Phase 2-B, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-NMDA Receptor Encephalitis and Assess Markers of Disease

Grant

Awarded By

Total Award Amount

  • 26191.00

    • Direct Costs

  • 18063.00

    • Sponsor Award Id

  • NN111

    • Contributor

  • Benjamin Jones   Principal Investigator  
  • Frank Benesh   Investigator  
  • John Rinker II   Investigator  
  • Khurram Bashir   Investigator  
  • Shruti Agnihotri   Investigator  
  • William Meador   Investigator